Market Overview:
The global gene therapy for CNS disorders market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing prevalence of neurological disorders, rising demand for novel therapies, and technological advancements in gene therapy. Based on type, the global gene therapy for CNS disorders market can be segmented into ex vivo and in vivo. Ex vivo is further sub-segmented into viral vector-based and nonviral vector-based therapies. In vivo is further sub-segmented into somatic cell therapy and stem cell therapy. Based on application, the global gene therapy for CNS disorders market can be segmented into hospitals, clinics, and others (research institutes/academic institutions). Geographically, the global gene therapy for CNS disorders market can be segmented into North America, Latin America, Europe Asia Pacific ,and Middle East & Africa . North America accounted for a major share of the global gene Therapy For CNS Disorders Market in 2017 owing to factors such as early adoption of advanced technologies by key players operating in this region coupled with increasing incidence rate of neurological diseases.
Product Definition:
Gene therapy is a technique that uses genes to treat or prevent diseases. The goal of gene therapy for CNS disorders is to replace or repair defective genes that are responsible for the disease. Gene therapy has the potential to be a powerful tool for treating CNS disorders, but it is still in its early stages of development. Clinical trials are currently underway to test the safety and effectiveness of gene therapy in patients with various CNS disorders, including Parkinson's disease, Huntington's disease, and spinal cord injury.
Ex Vivo:
Ex vivo is Latin for “with living tissues”. It is a biopharmaceutical industry term that refers to the practice of creating and maintaining patient-specific cell or tissue cultures in vitro before transplanting them into the patient for clinical trials. The main objective of ex vivo production is to produce safe, high titer, and effective protein therapeutics with minimal adverse effects.
In Vivo:
In vivo is Latin for "with life" and it's used to mean the process of testing a new medicine or treatment in living organisms. In vivo studies are important as they help scientists understand how the proposed therapy will perform in real life settings. This helps develop a solid base for clinical trials, especially when it comes to CNS disorders such as Parkinson’s disease, Alzheimer’s disease, Epilepsy and others.
Application Insights:
Based on application, the global market is segmented into Parkinson's disease, epilepsy, Alzheimer's disease, spinal cord injury and multiple sclerosis. The Parkinson¢â‚¬â„¢s disease segment dominated the overall market in 2017 owing to high availability of drugs for PD treatment. Moreover, this condition also affects a large number of people which boosts demand for gene therapy products.
The others segment includes Huntington's disease and Rett syndrome which are also relatively less prevalent conditions compared to PD. However, this does not prevent them from being profitable markets as both these disorders have attracted considerable attention from researchers over the past few years owing to their high unmet needs and potential as stand-alone therapies or in combination with other therapies (i.e., drug therapy).
Regional Analysis:
North America dominated the global market in 2017. This can be attributed to various factors such as favorable government initiatives, increasing prevalence of neurological disorders, and high adoption of gene therapy for treatment of genetic diseases in U.S. Moreover, presence of a large number of biotechnology companies engaged in developing novel therapies for CNS disorders is also expected to drive the regional market over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rising awareness about potential benefits associated with gene therapy and growing disposable income especially in emerging countries such as China and India. In addition, increased investment by governments & private entities coupled with supportive regulations are some other factors that can be attributed to this shift towards ex vivo/in vitro approaches over traditional animal models used for drug discovery thus far (Figure 1).
Growth Factors:
- Increasing prevalence of CNS disorders
- Growing demand for novel therapies for CNS disorders
- Rising public and private investment in gene therapy research and development
- Advances in gene delivery technologies
- Growing number of clinical trials for gene therapy treatments for CNS disorders
Scope Of The Report
Report Attributes
Report Details
Report Title
Gene Therapy for CNS Disorders Market Research Report
By Type
Ex Vivo, In Vivo
By Application
Hospitals, Clinics, Others
By Companies
Gilead (Kite Pharma), Amgen (BioVex), Novartis, Roche (Spark Therapeutics), Bluebird Bio
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
231
Number of Tables & Figures
162
Customization Available
Yes, the report can be customized as per your need.
Global Gene Therapy for CNS Disorders Market Report Segments:
The global Gene Therapy for CNS Disorders market is segmented on the basis of:
Types
Ex Vivo, In Vivo
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Hospitals, Clinics, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Gilead (Kite Pharma)
- Amgen (BioVex)
- Novartis
- Roche (Spark Therapeutics)
- Bluebird Bio
Highlights of The Gene Therapy for CNS Disorders Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Ex Vivo
- In Vivo
- By Application:
- Hospitals
- Clinics
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Gene Therapy for CNS Disorders Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Gene therapy is a treatment that uses genetic material to treat disorders of the central nervous system (CNS). This type of therapy can help restore function in damaged or malfunctioning parts of the brain and spinal cord. Gene therapy can also help improve symptoms associated with certain CNS disorders, such as epilepsy, Huntington's disease, and multiple sclerosis.
Some of the key players operating in the gene therapy for cns disorders market are Gilead (Kite Pharma), Amgen (BioVex), Novartis, Roche (Spark Therapeutics), Bluebird Bio.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Gene Therapy for CNS Disorders Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Gene Therapy for CNS Disorders Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Gene Therapy for CNS Disorders Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Gene Therapy for CNS Disorders Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Gene Therapy for CNS Disorders Market Size & Forecast, 2018-2028
4.5.1 Gene Therapy for CNS Disorders Market Size and Y-o-Y Growth
4.5.2 Gene Therapy for CNS Disorders Market Absolute $ Opportunity
Chapter 5 Global Gene Therapy for CNS Disorders Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Gene Therapy for CNS Disorders Market Size Forecast by Type
5.2.1 Ex Vivo
5.2.2 In Vivo
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Gene Therapy for CNS Disorders Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Gene Therapy for CNS Disorders Market Size Forecast by Applications
6.2.1 Hospitals
6.2.2 Clinics
6.2.3 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Gene Therapy for CNS Disorders Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Gene Therapy for CNS Disorders Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Gene Therapy for CNS Disorders Analysis and Forecast
9.1 Introduction
9.2 North America Gene Therapy for CNS Disorders Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Gene Therapy for CNS Disorders Market Size Forecast by Type
9.6.1 Ex Vivo
9.6.2 In Vivo
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Gene Therapy for CNS Disorders Market Size Forecast by Applications
9.10.1 Hospitals
9.10.2 Clinics
9.10.3 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Gene Therapy for CNS Disorders Analysis and Forecast
10.1 Introduction
10.2 Europe Gene Therapy for CNS Disorders Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Gene Therapy for CNS Disorders Market Size Forecast by Type
10.6.1 Ex Vivo
10.6.2 In Vivo
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Gene Therapy for CNS Disorders Market Size Forecast by Applications
10.10.1 Hospitals
10.10.2 Clinics
10.10.3 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Gene Therapy for CNS Disorders Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Gene Therapy for CNS Disorders Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Gene Therapy for CNS Disorders Market Size Forecast by Type
11.6.1 Ex Vivo
11.6.2 In Vivo
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Gene Therapy for CNS Disorders Market Size Forecast by Applications
11.10.1 Hospitals
11.10.2 Clinics
11.10.3 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Gene Therapy for CNS Disorders Analysis and Forecast
12.1 Introduction
12.2 Latin America Gene Therapy for CNS Disorders Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Gene Therapy for CNS Disorders Market Size Forecast by Type
12.6.1 Ex Vivo
12.6.2 In Vivo
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Gene Therapy for CNS Disorders Market Size Forecast by Applications
12.10.1 Hospitals
12.10.2 Clinics
12.10.3 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Gene Therapy for CNS Disorders Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Gene Therapy for CNS Disorders Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Gene Therapy for CNS Disorders Market Size Forecast by Type
13.6.1 Ex Vivo
13.6.2 In Vivo
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Gene Therapy for CNS Disorders Market Size Forecast by Applications
13.10.1 Hospitals
13.10.2 Clinics
13.10.3 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Gene Therapy for CNS Disorders Market: Competitive Dashboard
14.2 Global Gene Therapy for CNS Disorders Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Gilead (Kite Pharma)
14.3.2 Amgen (BioVex)
14.3.3 Novartis
14.3.4 Roche (Spark Therapeutics)
14.3.5 Bluebird Bio
